+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Pembrolizumab"

From
Precision Cancer Therapeutics, 2022 - Product Thumbnail Image

Precision Cancer Therapeutics, 2022

  • Report
  • November 2022
  • 154 Pages
  • Global
From
From
From
From
From
From
From
Head and Neck Cancer Therapeutics - A Global Market Overview - Product Thumbnail Image

Head and Neck Cancer Therapeutics - A Global Market Overview

  • Report
  • November 2024
  • 301 Pages
  • Global
From
From
From
From
PARP Inhibitor Market - Product Thumbnail Image

PARP Inhibitor Market

  • Report
  • May 2024
  • 200 Pages
  • Global
From
From
From
From
From
Bispecific antibody - Competitive landscape, 2023 - Product Thumbnail Image

Bispecific antibody - Competitive landscape, 2023

  • Report
  • May 2023
  • 450 Pages
  • Global
From
Loading Indicator

Pembrolizumab is a type of oncology drug used to treat certain types of cancer. It is a monoclonal antibody, which works by targeting and blocking a protein called PD-1, which is found on the surface of some cancer cells. This helps the body's immune system to recognize and attack the cancer cells. Pembrolizumab is used to treat a variety of cancers, including melanoma, non-small cell lung cancer, head and neck cancer, Hodgkin lymphoma, and urothelial carcinoma. It is also used in combination with other drugs to treat certain types of advanced or metastatic cancers. Pembrolizumab is approved by the US Food and Drug Administration (FDA) and is available in the US and other countries. It is typically administered intravenously, and the dosage and duration of treatment depend on the type and stage of cancer being treated. Some companies in the Pembrolizumab market include Merck & Co., Inc., Bristol-Myers Squibb, AstraZeneca, and Roche. Show Less Read more